The strategy is to expand cold chain capabilities to meet the upcoming demand in the wake of Covid-19
Envirotainer, a global provider of temperature-controlled air freight equipment and technology for pharmaceuticals, is increasing its RAP e2 network capacity in the US by 57 percent.
The four new RAP e2 stations in New York, Miami, Philadelphia and Seattle will increase the capacity to securely ship both Covid-19 vaccines as well as all other medicines that require high-quality temperature-controlled packaging solutions.
"
(Image credit: Envirotainer)" alignment="right"/>
The move will help bring the active temperature-controlled unit closer to the manufacturing hubs of the company’s pharmaceutical customers, according to Eddy Cojulun, chief sales officer at Envirotainer.
"In light of upcoming Covid-19 vaccine shipments and the expected demand surge that it will bring, having the right solution readily available will significantly reduce the time-to-market for these life-saving vaccines once they are ready for global distribution," Cojulun said.
Envirotainer's strategy is to expand capabilities across the globe to meet the upcoming demand. In addition, the company says it will be positioned to handle other forthcoming temperature-sensitive shipments that require a 2-8°C or -20°C controlled environment.
The company has been expanding its commercial offerings in the US over the past decade investing in both service delivery and operational capabilities, with a focus on an agile network model. The addition of JFK, MIA, PHL and SEA will bring the total number of RAP e2 stations for the mainland US to 11 along with one in Puerto Rico.
The other RAP e2 stations are located in northern New Jersey, Atlanta, Chicago, Indianapolis, Dallas/Fort Worth, Los Angeles, San Francisco and San Juan.
Envirotainer provides a total of 41 RAP e2 stations across the world, servicing cold-chain requirements. The four new US stations are commercially ready to receive bookings starting this week, according to the company.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
Is Compounding the Answer to the Semaglutide Shortage? Experts Weigh In
October 30th 2024In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.